Trump Extended the China Tariff Truce Again. Here's Why the August 11 Executive Order Isn't the Relief US Raw Material Importers Think You Think It Is

The Executive Order signed on 11 August 2025 did exactly what the market had been pricing in since the Stockholm communique two weeks earlier: it extended the Geneva tariff truce with China another 90 days, pushing the new expiry to 10 November 2025. Bond yields barely moved. Copper futures yawned. The S&P pushed a touch higher on headlines that read like relief.

But if you read the EO as a chemical raw material importer, relief is not the word. Three things happened in the same seven-day window that matter more than the headline extension:

• The reciprocal tariff regime for non-China origins resumed on 7 August after the short pause. Vietnam, Malaysia, India, Thailand, Indonesia and a long list of others went back on schedule.
• China removed 12 US companies from its Dual-Use list as a goodwill gesture inside the EO framework.
• Section 301 tariffs on Chinese-origin chemical inputs stayed in place. The April 4 rare earth export licence regime stayed in place. Neither was touched by the EO.

Put those together and what you have is not a relief rally. What you have is the stacked-duty equilibrium hardening into late 2025 while the headline number buys political cover. If you import chemical raw materials through any US-touching supply chain, or if your China-to-Melbourne flows price off the US marginal buyer, the stack is what you need to understand.

What the August 11 EO Actually Did

The EO extended by 90 days the tariff rates and the non-tariff arrangements agreed at Geneva in May and reaffirmed at Stockholm in late July. In practice:

On China-specific tariffs: The Geneva rate structure holds. The reciprocal rate on Chinese-origin goods stays at the reduced Geneva level. The incremental threat that had pushed rates toward 125% in April-May is off the table until at least 10 November.

On non-China origins: The short pause that had applied to the reciprocal regime through 7 August ended on schedule. Country-specific rates resumed against Vietnam, Malaysia, Thailand, Indonesia, India and roughly 60 other origins. For chemical importers who had rerouted Chinese supply through Southeast Asian transhipment in 2023-2024, this is the painful part of the EO: the reroute arbitrage got narrower, not wider.

On the Dual-Use list: MOFCOM removed 12 US companies from the Chinese Dual-Use list. The named companies were mid-tier specialty chemistry and equipment suppliers where the commercial damage of the listing had been disproportionate to the strategic signal. It’s a goodwill move inside the EO framework.

On Section 301: Untouched. The List 1, 2, 3 and 4A rates against Chinese-origin chemicals stay exactly where they’ve been. For a List 3 chemical input at the 25% Section 301 rate plus Most Favoured Nation duty plus any fentanyl-tranche uplift, the stack is unchanged.

On rare earth and critical mineral controls: Untouched. The 4 April 2025 licence regime on samarium, gadolinium, terbium, dysprosium, lutetium, scandium and yttrium, plus the expanded controls on permanent-magnet-related alloys, remains fully enforced. Licence approval times have lengthened through August as GACC and MOFCOM work through backlog.

So the EO gave you one ceiling held, one floor reset up on non-China origins, one goodwill signal, and two binding constraints left completely alone.

The Stacked Duty Picture for Chemical Raw Materials

This is where the actual landed cost lives. For an Australian importer, your exposure to the US tariff stack runs through three indirect channels: US-origin chemical inputs you buy, Chinese chemistry that prices off the US marginal buyer, and Southeast Asian transhipped volume that now carries reciprocal duty into the US. All three are inside the stack.

The stack on a typical Chinese-origin specialty chemical input into the US looks like this:

For a polymeric specialty like MDI or TDI classified under HS 2929, the stack on a Chinese-origin shipment into a US importer of record sits around MFN 6.5% plus Section 301 at 25% plus the reciprocal extension. Work it through a notional US$1,600 per MT FOB value and you’re looking at something in the region of US$500 to US$650 per MT of stacked duty depending on exact classification.

For rare earth content products like specialty catalysts using dysprosium or terbium doping, you layer the licence regime on top. The licence itself doesn’t add a percentage, but it adds lead time (now running 45 to 80 days instead of pre-April 2 to 3 weeks) and it adds optionality cost (you can’t just re-source mid-quarter if a licence application is delayed).

The Australian importer whose Melbourne landed cost is partly a function of the US marginal buyer picks up a price that bakes in that stack. Your FOB China quote on a rare-earth-containing catalyst charge is higher than it would be in a counterfactual world without the April 4 licence regime, because the Chinese supplier prices to the US buyer who carries the stack and then gives you the same price.

The Non-China Reroute Problem

Through 2023 and early 2024, a lot of Chinese specialty chemistry rerouted through Vietnam, Malaysia and Thailand to access lower reciprocal rates and dodge the Section 301 List exposure where the HS classification allowed. The reroute architecture was real and in some cases legitimate (actual processing in Vietnam adding substantial transformation) and in some cases a paper exercise that CBP started enforcing against in Q4 2024.

The August 7 resumption of reciprocal rates against non-China origins closed the window further. For an Australian importer whose supplier is shipping from Ho Chi Minh City or Port Klang with Chinese intermediate input, two things now matter:

One: Rules of origin substantiation. CBP is asking for detailed transformation documentation on Vietnam-origin and Malaysia-origin chemical shipments where the intermediate is Chinese. If your supplier can’t substantiate substantial transformation, the shipment defaults to Chinese origin and picks up the full Section 301 plus reciprocal stack.

Two: The Southeast Asian rate itself. Vietnam’s reciprocal rate resumed at the country-specific level set in the April framework. Malaysia and Thailand likewise. The reroute saving against a direct Chinese shipment is narrower than it was, and for some HS lines it’s negative once you factor the transhipment and documentation cost.

For Australian importers sourcing through Southeast Asian suppliers who rely on Chinese intermediate, the August 7 resumption means your supplier’s US-facing cost just went up, and if they sell into Australia at the same FOB, they’re compressing their own margin. Expect some of them to push for price increases through Q3 or to degrade their grade mix.

The Rare Earth Licence Regime: Still Binding

The April 4 2025 export licence regime on seven rare earth elements, plus the expanded controls on permanent magnet alloys published in May, was the most consequential Chinese export control action of the year. The EO did nothing to touch it.

What that means in practice through August and September:

Licence approval timelines are lengthening. MOFCOM set expected review at 45 business days. Actual approvals are running 55 to 80 business days for new applicants, faster for established relationships with clean compliance histories. The backlog is real and growing.

The licence regime is being used as a commercial lever. End-use certificates are scrutinised. Defence-adjacent end uses are frequently declined or delayed without formal refusal. Commercial end uses with clear documentation are approved but slowly.

Some specialty chemistry categories are caught indirectly. Catalysts using dysprosium or terbium-doped cordierite. Some phosphor precursors. Magnetic separation media in certain mineral processing chemistry. Battery precursor materials with rare earth intermediates. If your supplier uses any of these as a minor input, the licence regime creates a backdoor on your supply even if the primary chemistry is unregulated.

The workaround is not a workaround. Some mid-tier Chinese suppliers have proposed substituting rare earth content or reformulating to cerium and lanthanum inputs that are outside the regime. In a handful of catalyst and phosphor applications this is technically viable. In most catalyst and specialty applications the performance gap is real and the reformulation carries a lead time and validation cost that defeats the saving.

For Australian importers receiving rare-earth-dependent chemistry, build the licence timeline into your production planning. Stop assuming you can re-source inside a quarter. Stop assuming the quoted lead time matches the licence-approved dispatch date.

The Timeline That Matters

Here’s the calendar every Australian chemical importer should have pinned to the wall for the rest of 2025:

The window that matters most is Oct 20 to Nov 10. If USTR and MOFCOM signal a third 90-day extension, the FOB China market softens another 2% to 4% and you get a tactical buying window for Q1 2026 volume. If they signal escalation or let the EO lapse without renewal, FOB prints spike in days and your November shipping commitments become a serious margin risk.

Don’t carry more than two weeks of unfixed spot exposure into early November.

Landed Cost Build with the Full Stack

Work a concrete example to see how this compounds. You’re importing a 400 MT quarterly shipment of a specialty catalyst charge from a Chinese supplier who uses a dysprosium-doped cordierite substrate, landing into Melbourne.

Step one: FOB China. The supplier’s FOB Ningbo quote for August loading is US$9,400 per MT. That’s already up roughly 8% from the pre-April 4 2025 baseline because the dysprosium licence regime lifted the substrate input cost and the supplier is passing the cost through.

Step two: Licence lead time. The licence application was filed on 15 June for October dispatch. Approved 12 August. That’s 58 business days. Your production scheduling needs to reflect that you can’t re-source mid-quarter without taking a 10 to 14 week hit on the next licence application.

Step three: Freight. Stable direct Asia-Oceania string. US$2,650 per 40-foot, 20 containers for the shipment. US$53,000 total.

Step four: Insurance and finance. Insurance at 0.35% of CIF, roughly US$13,350. Letter of credit cost at 1.2% annualised over 90 days, roughly US$11,400.

Step five: Australian import costs. Customs duty at 5% on CIF. GST at 10% on CIF plus duty. Customs broker and handling, around AUD 4,200.

Run the numbers:

Now run the counterfactual without the rare earth licence regime, using a pre-April FOB of US$8,700 per MT:

The rare earth licence regime cost you US$781 per MT of landed cost on this particular charge. Across a 400 MT quarterly shipment, US$312,292. Across a year of four quarterly shipments, US$1,249,168. None of that shows up on the EO headline. None of it was touched by the August 11 extension.

What the 12-Company Dual-Use Removal Means (and Doesn’t)

The goodwill removal of 12 US companies from the Chinese Dual-Use list was a calibrated gesture. It signals that the framework allows for specific adjustments inside the broader truce. It does not signal that the broader export control architecture on either side is loosening.

For Australian importers, the practical read:

• If you have a US-origin specialty input in your supply chain where the US supplier was on the Dual-Use list, check the removal schedule and confirm their re-export licence status.
• Don’t extrapolate the removal to a general relaxation. The 12 companies were specific cases. The system is otherwise fully intact.
• Watch for reciprocal gestures from USTR around BIS entity list removals. If there’s a symmetric de-escalation signal in late Q3, the tone heading into November sweetens.

Risks the Optimistic Read Misses

Three things can still go wrong before November 10:

One: A flashpoint incident. Any single high-profile export control violation, sanctions evasion prosecution, or critical mineral incident could derail the framework in a news cycle. The truce extends the tariff posture but does not change the underlying structural tension.

Two: Rare earth licence tightening. MOFCOM has the authority to tighten end-use scrutiny or add elements to the controlled list at any time. A handful of commentators in Beijing have floated adding neodymium and praseodymium to the licence regime in H2 2025. That would hit a much wider catalyst, magnet and specialty chemistry universe.

Three: Australian-specific measures. Most of this analysis has been about the US stack as it flows through to Melbourne landed costs. Australia has its own anti-dumping measures, biosecurity regime and specific country-of-origin rules. The US framework is not a substitute for your domestic compliance picture. If you’re bringing in specialty chemistry under an anti-dumping measure or a tariff concession, your Australian duty profile is doing its own thing and needs to be modelled separately.

What To Actually Do Between Now and November 10

1. Pull every open contract and PO with Chinese suppliers and audit the rare earth exposure. Tag anything with dysprosium, terbium, samarium, gadolinium, lutetium, scandium or yttrium content. Confirm licence status and lead time for the next two shipments.
2. Push Q4 contract refreshes on any annual terms struck during the April-May spike. The EO extension gives you a 2% to 4% softening window you should be capturing.
3. Audit Southeast Asian suppliers for rules-of-origin substantiation. Demand transformation documentation in writing. If they can’t produce it, your shipment is defaulting to Chinese origin for any US-touching volume and your supplier’s landed cost will reflect the full stack.
4. Build a November 10 contingency plan. Identify which contracts can be extended, which need to be fixed before the truce expiry, and which have enough flexibility to absorb a renegotiated rate.
5. Book Q1 2026 shipping capacity now. Carriers will start pricing CNY-affected space in September. The combination of potential tariff uncertainty in November and CNY factory closures in February means front-loaded Q1 volume will get expensive late.
6. Update your internal landed cost model with the full stacked-duty view. If you’re still quoting internal stakeholders at pre-April numbers, the November review will be painful.

The August 11 EO was not the relief the headlines suggested. It was a 90-day political cover for an equilibrium that has already hardened. Australian importers who treat the extension as a window for tactical action will land Q4 and Q1 2026 with intact margins. Those who read the headline and stand down on their supply chain work will not.

If you want a working session on your open book with the full stack modelled against your Q4 and Q1 2026 exposure, that’s exactly what we do. Send us the contracts and the PO list and we’ll show you where the stack is biting hardest and where the tactical moves sit inside the next 90 days.